IPF call options

Surprise readouts from two programs in idiopathic pulmonary fibrosis have generated over $1.4 billion in market value, and there could still be plenty of upside ahead.

After market close on Aug. 7, FibroGen Inc. (NASDAQ:FGEN) reported that its pamrevlumab (FG-3019) met the primary endpoint of reducing the loss of forced vital capacity (FVC) percent predicted from baseline to week 48 in a Phase II trial vs. placebo (2.85% vs. 7.17%, p=0.0331) in patients with IPF...